{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:10:09Z","timestamp":1777421409962,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of the study was to review the pharmacologic and clinical profile of adalimumab-adbm (BI 695501), the first interchangeable biosimilar for treatment of inflammatory diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A PubMed search was conducted from inception to December 2021 using the keywords BI 695501 and adalimumab-adbm. Information was also obtained from published abstracts and package inserts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Phase 1, 2 and 3 studies plus relevant literature on adalimumab-adbm pharmacologic and clinical profile were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Adalimumab-adbm approval was based on a series of phase 3 VOLTAIRE trials, which evaluated the biosimilar\u2019s efficacy and safety in the treatment of moderate to severe Crohn\u2019s disease, rheumatoid arthritis, and psoriasis. Interchangeability status was granted based on data from the VOLTAIRE-X trial. The VOLTAIRE and VOLTAIRE-X studies demonstrated comparable efficacy and safety between adalimumab-adbm and reference adalimumab. Common adverse events included infections and injection site reactions. Similar to reference adalimumab, adalimumab-adbm contains black box warnings related to serious infections and malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Adalimumab-adbm is the first interchangeable biosimilar to be approved for inflammatory diseases and has the potential to improve patient access to treatment while decreasing medication-related costs. However, it will not be commercially available for patient use until 2023 and its adoption into clinical practice may face potential barriers seen with other biosimilars.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As an interchangeable biosimilar with comparable efficacy and safety to reference adalimumab, adalimumab-adbm is an important advance toward cost-effective management of inflammatory diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221082196","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T02:47:46Z","timestamp":1649386066000},"page":"1356-1364","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases"],"prefix":"10.1177","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-9506","authenticated-orcid":false,"given":"Shubha","family":"Bhat","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-8976","authenticated-orcid":false,"given":"Maitri","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Dermatology, University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Duly","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-1784","authenticated-orcid":false,"given":"David","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"bibr1-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa116."},{"key":"bibr2-10600280221082196","unstructured":"Abbott Laboratories. Humira (adalimumab) [package insert]. Published 2016. Accessed February 23, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf."},{"key":"bibr3-10600280221082196","unstructured":"Implementation of the Biologics Price Competition and Innovation Act of 2009. Published 2016. Accessed December 29, 2021. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/implementation-biologics-price-competition-and-innovation-act-2009."},{"key":"bibr4-10600280221082196","unstructured":"Biosimilar and Interchangeable Products. Published 2017. Accessed December 29, 2021. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products."},{"key":"bibr5-10600280221082196","unstructured":"Biosimilar Interchangeability: 9 Things to Consider. Published 2018. Accessed December 29, 2021. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"bibr6-10600280221082196","unstructured":"Biosimilar Product Information. Published 2021. Accessed December 29, 2021. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"bibr7-10600280221082196","unstructured":"Biosimilar and Interchangeable Biologics: More Treatment Choices. Accessed December 29, 2021. https:\/\/www.fda.gov\/consumers\/consumer-updates\/biosimilar-and-interchangeable-biologics-more-treatment-choices."},{"key":"bibr8-10600280221082196","unstructured":"Hagen T. FDA Grants Interchangeable Status for Boehringer Ingelheim\u2019s Adalimumab Biosimilar (Cyltezo). AJMC: The Center for Biosimilars. Published 2021. Accessed December 29, 2021. https:\/\/www.centerforbiosimilars.com\/view\/fda-grants-interchangeable-status-for-boehringer-ingelheim-s-adalimumab-biosimilar-cyltezo-"},{"key":"bibr9-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/409396"},{"key":"bibr10-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.08.013."},{"key":"bibr11-10600280221082196","unstructured":"Boehringer Ingelheim. Cyltezo (adalimumab-adbm) [package insert]. Published 2021. Accessed February 23, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761058lbl.pdf."},{"key":"bibr12-10600280221082196","unstructured":"Anderson H, Kirshner S. Center for Drug Evaluation and Research: BLA 761058 Cyltezo (Adalimumab-adbm) Quality Review. FDA. Published 2017. Accessed January 26, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761058Orig1s000ChemR.pdf."},{"key":"bibr13-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1255724."},{"key":"bibr14-10600280221082196","doi-asserted-by":"publisher","DOI":"10.3390\/antib8010021."},{"key":"bibr15-10600280221082196","unstructured":"Nikolov NP, Chowdhury BA. Application Number: 761058Orig1s000 Summary Review. Center for Drug Evaluation and Research. Published 2017. Accessed February 3, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761058Orig1s000SumR.pdf."},{"key":"bibr16-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212245."},{"key":"bibr17-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1645114."},{"key":"bibr18-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00252-1."},{"key":"bibr19-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1851362."},{"key":"bibr20-10600280221082196","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000722896.32651.d6."},{"key":"bibr21-10600280221082196","unstructured":"The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira\u00ae and BI 695501 in Patients With Plaque Psoriasis. Published 2021. Accessed December 29, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03210259."},{"key":"bibr22-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2018.1472572."},{"key":"bibr23-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.062."},{"key":"bibr24-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key208."},{"key":"bibr25-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07114-y."},{"key":"bibr26-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa297."},{"key":"bibr27-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00256-x."},{"key":"bibr28-10600280221082196","unstructured":"Requests that the FDA interpret the term \u201cstrength\u201d in section 351(k) of the PHS Act for parenteral solutions to mean \u201ctotal drug content,\u201d without regard to concentration. Published 2021. Accessed December 29, 2021. https:\/\/www.regulations.gov\/docket\/FDA-2020-P-2247."},{"key":"bibr29-10600280221082196","doi-asserted-by":"publisher","DOI":"10.1177\/12034754211048674."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221082196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221082196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221082196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:47Z","timestamp":1777375007000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221082196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/10600280221082196"],"URL":"https:\/\/doi.org\/10.1177\/10600280221082196","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}